PRME 1W: FDA Opens the Gates. DNA Accumulation CompletePrime Medicine, Inc.BATS:PRMETotoshkaTradesThe long-term chart of PRME reveals a classic institutional accumulation stage and deliberate position building by a large market participant, which has been developing since November 2025 within a rounding bottom structure. The key support level at 2.67 has been tested four times since May, consistently demonstrating a strong buy-side limit reaction, which confirms that this zone is being heavily defended by smart money. This week, the accumulation phase transitioned into an active markup stage, evidenced by a powerful upward price push. This momentum is confirmed by an anomalous surge in trading volume on the NASDAQ, exceeding 8.06 million shares in a single session. Such volume indicates aggressive market buying by the market maker, while technical indicators have simultaneously broken out of their consolidation ranges, confirming strong bullish momentum. In tandem with the technical setup, the primary fundamental driver for the uptrend is the official FDA clearance to initiate clinical trials for the company’s flagship prime editing candidate, PM647. Additional fundamental stability is provided by the complete resolution of prior patent disputes with Beam Therapeutics, which effectively eliminated key legal risks for the business. Within the current market structure, the key level for further medium-term expansion lies at the strong resistance zone of 4.91. A weekly acceptance and consolidation above this threshold will unlock direct upside potential, targeting the 6.98 level first, followed by the primary macro trend target at 10.77.